HC Wainwright Issues Pessimistic Forecast for BioNTech (NASDAQ:BNTX) Stock Price
BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...
Rezolve AI (NASDAQ:RZLV) Coverage Initiated by Analysts at HC Wainwright
Investment analysts at HC Wainwright began coverage on shares of Rezolve AI (NASDAQ:RZLV – Get Free Report) in a research ...
Fintel on MSN20h
HC Wainwright & Co. Upgrades Sarepta Therapeutics (SRPT)
Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...
Kalkine Media23h
Could HC Wainwright's Appraisal Backfire on Cabaletta Bio?
Highlights,Cabaletta Bio receives a favorable evaluation from HC Wainwright.,An institutional review brings renewed focus to ...
Fintel on MSN2d
HC Wainwright & Co. Initiates Coverage of Virax Biolabs Group (VRAX) with Buy Recommendation
Fintel reports that on March 31, 2025, HC Wainwright & Co. initiated coverage of Virax Biolabs Group (NasdaqCM:VRAX) with a ...
H.C. Wainwright Sticks to Its Hold Rating for Galectin Therapeutics (GALT)
H.C. Wainwright analyst Ed Arce maintained a Hold rating on Galectin Therapeutics (GALT – Research Report) today. The company’s shares closed ...
H.C. Wainwright Sticks to Their Hold Rating for Mawson Infrastructure Group (MIGI)
H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Mawson Infrastructure Group (MIGI – Research Report) today. The company’s shares ...
Kalkine Media1d
Vanda Pharmaceuticals (NASDAQ:VNDA) has been given a Buy rating by HC Wainwright.
Highlights,Vanda Pharmaceuticals posts improved earnings, surpassing market expectations.,Company executives increase stock ...
Investing6d
Nektar at H.C. Wainwright Conference: Strategic Updates on Respegg Trials
On Thursday, 27 March 2025, Nektar Therapeutics (NASDAQ: NKTR) participated in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The company provided a strategic ...
Aptose Biosciences price target raised to $6 from $2 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2 and keeps ...
Investing6d
Aclaris at H.C. Wainwright Conference: Strategic Moves in Immuno-Inflammatory Diseases
Mitchell Kapoor, Senior Biotech Analyst, H. C. Wainwright: Hi, everyone. My name is Mitchell Kapoor. I’m a senior biotech analyst at H. C. Wainwright. Today, I’m pleased to be joined by the ...